Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07833007

Metabolic Syndrome Resposne to Dietary Limitations in Familial Mediterranean Fever in Adolescents

metabolic syndrome may be prevalent in familial Mediterrean fever. Dietary limitations are main treatment in metabilc syndrome

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Familial Mediterranean Fever (FMF ) Congenital, Hereditary, and Neonatal Diseases and Abnormalities Familial Mediterranean Fever Genetic Diseases, Inborn Glucose Metabolism Disorders Hereditary Autoinflammatory Diseases Hyperinsulinism Insulin Resistance Metabolic Diseases Metabolic Syndrome Nutritional and Metabolic Diseases

Age range

13 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

forty metabolic syndrome participants (adolescents) with familial Mediterrean fever divided equally in to study group received low calorie diet for 3 months and control group who will no change their dietary habits

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • metabolic syndrome
  • familial mediterreanean fever

Exclusion criteria

  • cardiac diseases
  • repsiratory diseases
  • tumors

Treatment and study plan

Low calorie diet

Behavioral

metabolic syndrome participants (adolescents) with familial Mediterrean fever will received low calorie diet for 3 months

Primary outcomes

  1. fasting blood glcuose

    Time frame: it will be assessed after 12 weeks

    it will be assessed in plasma

Secondary outcomes

  1. body mass index

    Time frame: it will be assessed after 12 weeks

    it will be assessed while patients were on empty stomach and bladder

  2. waist circumference

    Time frame: it will be assessed after 12 weeks

    it will be assessed via tape measurement

  3. high density lipoprotein

    Time frame: it will be assessed after 12 weeks

    it will be assessed in plasma

  4. triglycerides

    Time frame: it will be assessed after 12 weeks

    it will be assessed in plasma

  5. systolic blood pressure

    Time frame: it will be assessed after 12 weeks

    it will be assessed from brachial artery

  6. diastolic blood pressure

    Time frame: it will be assessed after 12 weeks

    it will be assessed from brachial artery

  7. C reactive protein

    Time frame: it will be assessed after 12 weeks

    it will be assessed in plasma

Study contacts

Contact information is provided by the study sponsor or research team.

Ali Ismail, PhD

CONTACT

[email protected]

+201005154209

Ali mohamed, PhD

CONTACT

[email protected]

+201033321109

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Sep 22, 2026
Registry last updated
Sep 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.